# South America Non Alcoholic Steatohepatitis Biomarkers Market

> South America Non-Alcoholic Steatohepatitis Biomarkers Market Research Report By Type (Hepatic Fibrosis Biomarkers, Serum Biomarkers, Oxidative Stress Biomarkers, Apoptosis Biomarkers, Others), By End User (Research Institutes and Academics, Diagnostic Centres, Pharmaceutical Companies and CROs, Hospitals and Clinics, Others) and By Regional (Brazil, Mexico, Argentina, Rest of South America) - Growth & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 2.36%
- **2024:** $ 15 Million
- **2025:** $ 15.35 Million
- **2035:** $ 19.39 Million
- **Key Players:** Gilead Sciences (US), Intercept Pharmaceuticals (US), Echosens (FR), Celerion (US), Genfit (FR), Pfizer (US), Bristol-Myers Squibb (US), Novartis (CH), Hepion Pharmaceuticals (US)

**Report ID:** MRFR/HC/47964-HCR · **Pages:** 200 · **Author:** Vikita Thakur & Rahul Gotadki · **Last Updated:** April 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/south-america-non-alcoholic-steatohepatitis-biomarkers-market-49718

---

## Market Summary

## **South America Non-Alcoholic Steatohepatitis Biomarkers Market Overview**

As per MRFR analysis, the South America Non-Alcoholic Steatohepatitis Biomarkers Market Size was estimated at 9.6 (USD Million) in 2023. The South America Non-Alcoholic Steatohepatitis Biomarkers Market Industry is expected to grow from 12(USD Million) in 2024 to 160 (USD Million) by 2035. The South America Non-Alcoholic Steatohepatitis Biomarkers Market CAGR (growth rate) is expected to be around 26.551% during the forecast period (2025 - 2035)

**Key South America Non-Alcoholic Steatohepatitis Biomarkers Market Trends Highlighted**

The South America Non-Alcoholic Steatohepatitis (NASH) Biomarkers Market is witnessing significant market trends driven by the increasing prevalence of metabolic disorders such as obesity and diabetes in the region. Governments in South America have been active in promoting awareness and the need for early diagnosis of liver diseases, which is a key factor pushing for the adoption of NASH biomarkers. 

Countries like Brazil and Argentina are putting in place health initiatives that focus on lifestyle changes and regular health check-ups, thereby increasing the demand for effective diagnostic tools. There are also ample opportunities to be explored in this market, particularly in enhancing research and development efforts for the identification of new biomarkers.The collaboration between local healthcare providers and international pharmaceutical companies is becoming more prevalent, which could facilitate innovative solutions tailored to the needs of the South American population.

Additionally, as the regulatory framework evolves to support the approval process for new biomarkers, this could encourage investments in research focused on NASH in the region.

Recent trends indicate a growing preference for non-invasive diagnostic methods among healthcare providers, reflecting a shift from traditional liver biopsy procedures to advanced biomarker testing. The increasing availability of advanced technologies, coupled with the rising number of healthcare facilities capable of conducting these tests, is leading to improved patient outcomes.Lastly, the ongoing challenges posed by the COVID-19 pandemic have also steered focus towards digital health solutions, emphasizing telemedicine and remote patient monitoring, which may significantly impact the NASH biomarkers market in South America. All these dynamics are reshaping the landscape of the NASH biomarkers market in the region.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

**South America Non-Alcoholic Steatohepatitis Biomarkers Market Drivers**

**Rising Prevalence of Non-Alcoholic Fatty Liver Disease**

The South America Non-Alcoholic Steatohepatitis Biomarkers Market Industry is significantly influenced by the rising incidence of Non-Alcoholic Fatty Liver Disease (NAFLD) throughout the region. The need for efficient diagnostic biomarkers is further increased by the fact that more than 20% of individuals in South America suffer from NAFLD, according to the Pan American Health Organization. Both public health initiatives and corporate sector expenditures in research and development are motivated by this concerning statistic, which emphasizes the pressing need for precise detection and biomarker development to meet the growing health burden. 

Furthermore, according to Brazilian healthcare surveys, a significant portion of hospital admissions are caused by liver-related illnesses, which makes investing in biomarkers for improved management and treatment options financially necessary. The South America Non-Alcoholic Steatohepatitis biomarkers market is anticipated to increase quickly as groups like the Brazilian Society of Hepatology stress the value of early detection.

**Supportive Government Policies and Funding**

Government initiatives aimed at improving healthcare infrastructure and disease management in South America are one of the critical drivers influencing the South America Non-Alcoholic Steatohepatitis Biomarkers Market Industry. Several South American countries have launched national health programs to combat chronic liver diseases. For instance, the Argentinian government allocated substantial funding to health campaigns focused on liver disease awareness and prevention, resulting in increased investment in for Research and Development of diagnostic tools.

The Brazilian Federal Ministry of Health has also introduced measures to enhance liver disease research and biomarker studies, thus creating a favorable regulatory environment. These policy-driven efforts not only facilitate public health improvements but also encourage industry players to engage in the commercialization of innovative biomarkers.

**Growing Focus on Personalized Medicine**

The shift towards personalized medicine in South America is another essential factor fueling growth in the South America Non-Alcoholic Steatohepatitis Biomarkers Market Industry. Personalized medicine allows tailored treatment plans based on individual patient profiles, particularly in chronic conditions like Non-Alcoholic Steatohepatitis (NASH).

Clinical studies from institutions like the University of So Paulo have indicated that personalized approaches significantly improve treatment outcomes in liver disease patients, which is driving the demand for innovative biomarkers that can guide personalized protocols.Additionally, the emergence of biotechnology firms specializing in biomarker discovery aligns with the demand for individualized treatments, ultimately enhancing patient care and paving the way for a larger market presence.

**Increasing Public Awareness and Education**

Enhanced public awareness and education regarding liver diseases, particularly Non-Alcoholic Steatohepatitis, has become a crucial market driver in the South America Non-Alcoholic Steatohepatitis Biomarkers Market Industry. Awareness campaigns led by organizations like the Latin American Association for the Study of the Liver are effectively educating the public about the risks associated with NAFLD and NASH, hence generating greater demand for diagnostic solutions.Data suggests that countries with proactive health education programs, such as Chile, have witnessed a noticeable rise in screenings for liver disease, resulting in an increased market potential for biomarkers.

This trend underscores the importance of educational initiatives in improving early diagnosis and treatment outcomes, ultimately stimulating market growth.

**South America Non-Alcoholic Steatohepatitis Biomarkers Market Segment Insights**

**Non-Alcoholic Steatohepatitis Biomarkers Market Type Insights**

The South America Non-Alcoholic Steatohepatitis Biomarkers Market is characterized by a diverse range of types that play a crucial role in the detection and management of the disease. The primary types within this market include Hepatic Fibrosis Biomarkers, Serum Biomarkers, Oxidative Stress Biomarkers, Apoptosis Biomarkers, and Others. Hepatic Fibrosis Biomarkers are significant due to their ability to assess liver scarring and fibrosis progression, thus aiding in timely interventions and treatment strategies. This particular type is pivotal for clinicians, as it aligns closely with clinical outcomes and can help reduce the need for invasive liver biopsies. 

Serum Biomarkers are also vital, as they are commonly utilized in non-invasive tests, providing swift insights into liver health without requiring extensive procedures. This non-invasive nature often results in higher patient compliance, making them a preferred choice in many clinical settings. Oxidative Stress Biomarkers serve a unique function as indicators of oxidative damage, which is a recognized contributor to liver disease progression. By monitoring these biomarkers, healthcare professionals can gauge the impact of various therapeutic interventions and lifestyle changes. 

Apoptosis Biomarkers emphasize the mechanisms of cell death in the liver, offering insights into disease progression and potential therapeutic targets. Lastly, the “Others” category encapsulates various emerging biomarkers that may offer novel insights into the pathophysiology of non-alcoholic steatohepatitis, underscoring the dynamic nature of this market segment. Each of these types plays a distinct role in the continuum of care for patients with non-alcoholic steatohepatitis, highlighting the need for ongoing research and development in the South America Non-Alcoholic Steatohepatitis Biomarkers Market to address the increasing prevalence of liver diseases in the region. 

With rising awareness and advancements in biomarker technologies, this market segment is expected to witness significant traction, driven by increasing healthcare expenditure and a growing focus on preventive healthcare measures across South America.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

**Non-Alcoholic Steatohepatitis Biomarkers Market End User Insights**

The South America Non-Alcoholic Steatohepatitis Biomarkers Market, particularly within the End User segment, showcases a diverse array of key players, including Research Institutes and Academics, Diagnostic Centres, Pharmaceutical Companies and Contract Research Organizations, Hospitals and Clinics, and others. Research Institutes and Academics are vital in advancing the understanding and development of biomarkers, driving innovation through a robust pipeline of research aimed at enhancing diagnosis and treatment protocols. 

Diagnostic Centres play a crucial role in implementing and validating these biomarkers in clinical use, ensuring that patients receive timely and accurate assessments of their liver health.The presence of Pharmaceutical Companies and Contract Research Organizations contributes significantly, as they facilitate the development and commercialization of new therapeutics targeting Non-Alcoholic Steatohepatitis, thereby fueling growth opportunities in this field. Hospitals and Clinics represent the frontline of healthcare, where these biomarkers are increasingly integrated into routine practice, leading to improved patient outcomes and a better understanding of disease prevalence. 

The segmentation emphasizes the collaborative efforts across these various End Users, indicating a concerted approach to tackling Non-Alcoholic Steatohepatitis in South America, which is becoming a pressing health challenge in the region.Overall, this sector is poised to play an instrumental role in addressing the significant healthcare needs associated with liver diseases.

**South America Non-Alcoholic Steatohepatitis Biomarkers Market Key Players and Competitive Insights**

The South America Non-Alcoholic Steatohepatitis Biomarkers Market is witnessing significant growth driven by the increasing prevalence of metabolic disorders, rising awareness about liver diseases, and advancements in biomarker discovery and diagnostic technologies. This market is characterized by intense competition as key players strive to establish their presence, drive innovation, and secure partnerships within the healthcare landscape. 

The dynamics of this market are influenced by the regulatory environment, along with the ongoing research into effective management and treatment options for Non-Alcoholic Steatohepatitis (NASH). Firms operating in this space are focusing on developing robust biomarkers that can help in the early diagnosis of NASH, thereby facilitating timely intervention and improving patient outcomes. 

The competitive landscape is marked by both established companies and emerging firms, each aiming to leverage their expertise and resources to capture market share.Illumina has established a strong foothold in the South America Non-Alcoholic Steatohepatitis Biomarkers Market through its cutting-edge genomic technologies, which aid in the identification and validation of NASH-related biomarkers. The company’s advanced sequencing platforms and array technologies are instrumental in furthering research into liver diseases, enabling accurate diagnostics and personalized medicine approaches. Illumina’s commitment to innovation is reflected in its continuous investment in research and development, which empowers healthcare professionals in South America to better understand NASH. 

Additionally, its collaborative partnerships with local research institutions and healthcare providers enhance its market presence and support the development of tailored solutions that meet regional needs. The synergy of advanced technology and strategic collaborations positions Illumina favorably within the competitive landscape of this market.BioRad Laboratories is another prominent player in the South America Non-Alcoholic Steatohepatitis Biomarkers Market, leveraging its extensive experience in diagnostics and life science research to deliver high-quality products and services. 

The company's portfolio includes a wide range of assays and diagnostic solutions designed to measure biomarkers associated with NASH, helping clinicians in accurate disease assessment and management. BioRad's established presence in South America is bolstered by its strong distribution network and robust customer support services, which facilitate the accessibility of its products across the region. The company also focuses on strategic mergers and acquisitions to enhance its capabilities and expand its market reach, aiming to stay ahead of technological advancements and emerging trends.

This proactive approach, combined with its commitment to innovation in biomarkers detection, positions BioRad Laboratories as a formidable competitor in the South American market for Non-Alcoholic Steatohepatitis.

**Key Companies in the South America Non-Alcoholic Steatohepatitis Biomarkers Market Include**

**South America Non-Alcoholic Steatohepatitis Biomarkers Market Industry Developments**

The South America Non-Alcoholic Steatohepatitis (NASH) Biomarkers Market has seen significant developments in recent months. Illumina has been expanding its technological footprint within this sector through collaboration with local healthcare providers to enhance genetic testing relevant to NASH. In August 2023, Abbott Laboratories announced the launch of a new diagnostic test aimed at identifying patients at risk of advancing liver disease in Brazil, enhancing early detection capabilities. Furthermore, in September 2023, Thermo Fisher Scientific increased its market presence by opening a new facility in Argentina, focusing on biomarker development for NASH. 

Merck KGaA has also made strides by partnering with universities in Colombia to advance research in biomarkers specific to metabolic diseases, including NASH. The market valuation in this region reflects a positive trajectory driven by increasing awareness of liver diseases and the rising demand for biomarker tests. Noteworthy is the growing collaboration between the pharmaceutical industry and local governments to address healthcare challenges associated with NASH, further solidifying the commitment to innovation in the South American healthcare landscape.

**South America Non-Alcoholic Steatohepatitis Biomarkers Market Segmentation Insights**

## Market Drivers

### Government Initiatives and Funding

Government initiatives and funding aimed at combating liver diseases are expected to bolster the non alcoholic-steatohepatitis-biomarkers market in South America. Various health authorities are recognizing the economic burden posed by liver diseases and are allocating resources for research and public health programs. This support may include grants for biomarker research, subsidies for diagnostic tools, and funding for awareness campaigns. Such initiatives could enhance collaboration between public and private sectors, fostering innovation in biomarker development. The financial backing from governments is likely to accelerate the introduction of new biomarkers into the market, thereby improving diagnostic capabilities and patient management.

### Increasing Awareness of Liver Health

The growing awareness regarding liver health in South America is driving the non alcoholic-steatohepatitis-biomarkers market. Public health campaigns and educational initiatives are emphasizing the importance of liver function and the risks associated with non alcoholic fatty liver disease (NAFLD). This heightened awareness is likely to lead to increased screening and diagnostic testing, thereby boosting demand for biomarkers. As a result, healthcare providers are more inclined to invest in advanced diagnostic tools, which could potentially enhance patient outcomes. The market for liver health diagnostics is projected to grow at a CAGR of approximately 8% over the next few years, indicating a robust opportunity for stakeholders in the non alcoholic-steatohepatitis-biomarkers market.

### Rising Incidence of Metabolic Disorders

The rising incidence of metabolic disorders, including diabetes and obesity, is significantly impacting the non alcoholic-steatohepatitis-biomarkers market in South America. As these conditions become more prevalent, the risk of developing non alcoholic steatohepatitis (NASH) increases, leading to a greater need for effective biomarkers for early detection and monitoring. Recent studies suggest that nearly 30% of the adult population in certain South American countries may be affected by obesity, which is a major risk factor for NASH. This trend is likely to drive investments in biomarker research and development, as healthcare systems seek to address the growing burden of metabolic diseases and their associated complications.

### Growing Demand for Personalized Medicine

The growing demand for personalized medicine is influencing the non alcoholic-steatohepatitis-biomarkers market in South America. As healthcare shifts towards tailored treatment approaches, the need for specific biomarkers that can guide therapy decisions is becoming increasingly apparent. Personalized medicine allows for more effective management of non alcoholic steatohepatitis by identifying patients who are most likely to benefit from particular interventions. This trend is expected to drive research into novel biomarkers and their applications in clinical settings. The market for personalized medicine is projected to expand significantly, with estimates suggesting a growth rate of approximately 12% over the next few years, indicating a promising landscape for the non alcoholic-steatohepatitis-biomarkers market.

### Technological Advancements in Diagnostic Tools

Technological advancements in diagnostic tools are playing a crucial role in shaping the non alcoholic-steatohepatitis-biomarkers market. Innovations such as non-invasive imaging techniques and advanced blood tests are enhancing the ability to detect and monitor liver diseases. These developments are likely to reduce the need for invasive liver biopsies, making diagnosis more accessible and less risky for patients. The integration of artificial intelligence and machine learning in data analysis is also expected to improve the accuracy of biomarker identification. As a result, the market is anticipated to witness a surge in demand for these advanced diagnostic solutions, potentially leading to a market growth rate of around 10% in the coming years.

## Future Outlook

The [Non Alcoholic Steatohepatitis Biomarkers Market](https://www.marketresearchfuture.com/reports/non-alcoholic-steatohepatitis-biomarkers-market-7984) is projected to grow at a 2.36% CAGR from 2025 to 2035, driven by increasing prevalence and advancements in diagnostic technologies.

**New opportunities:**

- Development of point-of-care testing devices for rapid biomarker analysis.
- Partnerships with healthcare providers for integrated biomarker screening programs.
- Investment in AI-driven data analytics for personalized treatment plans.

By 2035, the market is expected to achieve substantial growth, reflecting evolving healthcare needs.

## Segment Insights

### By Type: Hepatic Fibrosis Biomarkers (Largest) vs. Serum Biomarkers (Fastest-Growing)

In the South America non alcoholic-steatohepatitis-biomarkers market, the distribution of market share among various biomarker types reveals a clear dominance of Hepatic Fibrosis Biomarkers, which are essential for assessing liver damage. This segment holds the largest share, attributed to increasing prevalence of liver diseases and heightened awareness around early diagnostics. Serum Biomarkers follow closely behind, supported by extensive research and development initiatives aimed at identifying non-invasive testing methods to monitor disease progression. Growth trends in this segment are influenced by a combination of factors, including rising incidences of metabolic disorders and growing investments in healthcare infrastructure. As healthcare providers prioritize early detection and accurate diagnostics, Serum Biomarkers are rapidly gaining traction and are expected to exhibit the fastest growth. The shift towards personalized medicine further propels this segment as innovative biomarker solutions emerge to meet the evolving needs of clinicians and patients.

Hepatic Fibrosis Biomarkers (Dominant) vs. Serum Biomarkers (Emerging)

The Hepatic Fibrosis Biomarkers segment stands as the dominant player due to its crucial role in managing non alcoholic-steatohepatitis, enabling clinicians to gauge liver scarring effectively. With a wide range of assays available, these biomarkers facilitate timely interventions. In contrast, Serum Biomarkers are emerging as a noteworthy alternative, driven by advancements in technology and ongoing research to validate novel biomarkers for liver health assessment. Their ability to provide insights through blood tests enhances patient compliance and accessibility, propelling them into the spotlight as an innovative solution in the market.

### By End User: Diagnostic Centres (Largest) vs. Hospitals and Clinics (Fastest-Growing)

The distribution of the non-alcoholic steatohepatitis biomarkers market by end user reflects varied significance across different sectors. Diagnostic centres hold the largest market share, driven by their focused capabilities in testing and early diagnosis. Following closely, hospitals and clinics represent a growing segment, increasingly integrating advanced diagnostic technologies to cater to rising patient numbers and complex cases. Growth trends in this segment are propelled by increasing diagnostics demand and heightened awareness of non-alcoholic steatohepatitis. The pharmaceutical industry, along with contract research organizations (CROs), is also expanding its footprint, investing in R&D to devise effective biomarkers. This trend signifies a competitive landscape where diagnostic centres and hospitals continually innovate to meet evolving healthcare standards.

Diagnostic Centres (Dominant) vs. Hospitals and Clinics (Emerging)

Diagnostic centres serve as the cornerstone of the non-alcoholic steatohepatitis biomarkers market, providing specialized and accurate testing that fulfills regulatory and clinical needs. As they dominate the market, their established protocols and relationships with healthcare providers enhance patient outcomes. Conversely, hospitals and clinics are emerging players, increasingly adopting novel diagnostic approaches and technologies to improve service delivery. This shift is influenced by growing patient demand for non-invasive and efficient testing. As hospitals integrate these advancements, they aim to transition from traditional methods to a more patient-centered approach, ultimately boosting their market influence.

## Regional Market Share Analysis

### Brazil : Strong Growth Driven by Demand

Brazil holds a dominant market share of 6.5% in the non-alcoholic steatohepatitis (NASH) biomarkers market, valued at approximately $1.3 billion. Key growth drivers include increasing obesity rates and rising awareness of liver diseases. Government initiatives, such as the National Health Policy, promote early diagnosis and treatment, while improved healthcare infrastructure supports market expansion. The demand for innovative biomarkers is also on the rise, driven by a growing population seeking preventive healthcare solutions.

### Mexico : Growing Awareness and Investment

With a market share of 3.0%, Mexico's NASH biomarkers market is valued at around $600 million. The increasing prevalence of metabolic disorders and government-backed health campaigns are significant growth drivers. Regulatory frameworks are evolving to facilitate faster approvals for new biomarkers, while investments in healthcare infrastructure are improving access to diagnostic services. The demand for personalized medicine is also gaining traction, influencing consumption patterns.

### Argentina : Focus on Innovative Solutions

Argentina accounts for a 4.0% share of the NASH biomarkers market, valued at approximately $800 million. The market is driven by rising healthcare expenditure and a growing focus on innovative diagnostic solutions. Regulatory bodies are actively working to streamline the approval process for new biomarkers, enhancing market dynamics. The demand for effective treatments is increasing, particularly in urban areas where healthcare access is improving.

### Rest of South America : Potential for Growth and Development

The Rest of South America holds a 1.5% market share in the NASH biomarkers sector, valued at about $300 million. Key growth drivers include increasing healthcare investments and rising awareness of liver diseases. Regulatory policies are gradually becoming more supportive, encouraging the entry of new players. The market is characterized by diverse healthcare systems, with varying levels of access to diagnostic services across countries.

## Competitive Benchmarking

The non alcoholic-steatohepatitis-biomarkers market in South America is characterized by a dynamic competitive landscape, driven by increasing prevalence of non-alcoholic fatty liver disease (NAFLD) and a growing emphasis on early diagnosis and treatment. Key players such as Gilead Sciences (US), Intercept Pharmaceuticals (US), and Echosens (FR) are strategically positioned to leverage innovation and partnerships to enhance their market presence. Gilead Sciences (US) focuses on developing novel therapeutics and biomarkers, while Intercept Pharmaceuticals (US) emphasizes its pipeline of non-invasive diagnostic tools. Echosens (FR) is known for its advanced imaging technologies, which are crucial for the assessment of liver health, indicating a trend towards technological integration in diagnostics.
The market structure appears moderately fragmented, with several players vying for market share. Companies are increasingly localizing manufacturing and optimizing supply chains to enhance efficiency and reduce costs. This strategy not only improves responsiveness to local market demands but also strengthens their competitive positioning. The collective influence of these key players shapes a landscape where innovation and operational efficiency are paramount, fostering a competitive environment that encourages continuous improvement and adaptation.
In October 2025, Gilead Sciences (US) announced a collaboration with a leading South American research institution to advance the development of biomarkers for early detection of NAFLD. This partnership is expected to enhance Gilead's research capabilities and accelerate the introduction of innovative diagnostic solutions in the region. Such strategic alliances are likely to bolster Gilead's competitive edge by integrating local expertise and resources into their development processes.
In September 2025, Intercept Pharmaceuticals (US) launched a new initiative aimed at increasing awareness and accessibility of their non-invasive diagnostic tools across South America. This initiative is significant as it not only expands their market reach but also addresses the critical need for early diagnosis in a region where NAFLD prevalence is rising. By enhancing accessibility, Intercept positions itself as a leader in patient-centric solutions, potentially increasing its market share.
In August 2025, Echosens (FR) unveiled a new version of its FibroScan device, which incorporates advanced AI algorithms for improved accuracy in liver health assessment. This technological advancement is crucial as it aligns with the growing trend of digitalization in healthcare. By integrating AI, Echosens enhances the diagnostic capabilities of its devices, thereby reinforcing its competitive position in the market.
As of November 2025, the competitive trends in the non alcoholic-steatohepatitis-biomarkers market are increasingly defined by digital transformation, sustainability, and the integration of AI technologies. Strategic alliances are becoming more prevalent, facilitating knowledge sharing and resource optimization among key players. Looking ahead, the competitive differentiation is likely to evolve from traditional price-based competition to a focus on innovation, technological advancements, and supply chain reliability. This shift underscores the importance of developing robust, innovative solutions that meet the evolving needs of healthcare providers and patients alike.

## Recent News & Developments

The South America Non-Alcoholic Steatohepatitis (NASH) Biomarkers Market has seen significant developments in recent months. Illumina has been expanding its technological footprint within this sector through collaboration with local healthcare providers to enhance genetic testing relevant to NASH. In August 2023, Abbott Laboratories announced the launch of a new diagnostic test aimed at identifying patients at risk of advancing liver disease in Brazil, enhancing early detection capabilities. Furthermore, in September 2023, Thermo Fisher Scientific increased its market presence by opening a new facility in Argentina, focusing on biomarker development for NASH. 

Merck KGaA has also made strides by partnering with universities in Colombia to advance research in biomarkers specific to metabolic diseases, including NASH. The market valuation in this region reflects a positive trajectory driven by increasing awareness of liver diseases and the rising demand for biomarker tests. Noteworthy is the growing collaboration between the pharmaceutical industry and local governments to address healthcare challenges associated with NASH, further solidifying the commitment to innovation in the South American healthcare landscape.

## Report Scope

| MARKET SIZE 2024 | 15.0(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 15.35(USD Million) |
| MARKET SIZE 2035 | 19.39(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 2.36% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Gilead Sciences (US), Intercept Pharmaceuticals (US), Echosens (FR), Celerion (US), Genfit (FR), Pfizer (US), Bristol-Myers Squibb (US), Novartis (CH), Hepion Pharmaceuticals (US) |
| Segments Covered | Type, End User |
| Key Market Opportunities | Emerging biomarkers for non alcoholic steatohepatitis enhance diagnostic accuracy and treatment personalization. |
| Key Market Dynamics | Rising demand for non alcoholic steatohepatitis biomarkers driven by regulatory changes and technological advancements in South America. |
| Countries Covered | Brazil, Mexico, Argentina, Rest of South America |

## Frequently Asked Questions

**Q: What was the market valuation for non alcoholic-steatohepatitis biomarkers in 2024?**
A: The market valuation for non alcoholic-steatohepatitis biomarkers was $15.0 Million in 2024.

**Q: What is the projected market valuation for 2035?**
A: The projected market valuation for 2035 is $19.39 Million.

**Q: What is the expected CAGR for the market during the forecast period 2025 - 2035?**
A: The expected CAGR for the market during the forecast period 2025 - 2035 is 2.36%.

**Q: Which companies are considered key players in the market?**
A: Key players in the market include Gilead Sciences, Intercept Pharmaceuticals, Echosens, Celerion, Genfit, Pfizer, Bristol-Myers Squibb, Novartis, and Hepion Pharmaceuticals.

**Q: What are the main types of biomarkers in this market?**
A: The main types of biomarkers include Hepatic Fibrosis Biomarkers, Serum Biomarkers, Oxidative Stress Biomarkers, Apoptosis Biomarkers, and Others.

**Q: What was the valuation of Hepatic Fibrosis Biomarkers in 2024?**
A: The valuation of Hepatic Fibrosis Biomarkers was $3.0 Million in 2024.

**Q: How much is the Serum Biomarkers segment expected to grow by 2035?**
A: The Serum Biomarkers segment is expected to grow from $4.0 Million in 2024 to $5.0 Million by 2035.

**Q: What is the projected valuation for Diagnostic Centres by 2035?**
A: The projected valuation for Diagnostic Centres is expected to rise from $3.0 Million in 2024 to $3.75 Million by 2035.

**Q: Which end user segment had the highest valuation in 2024?**
A: The Pharmaceutical Companies and CROs segment had the highest valuation at $4.5 Million in 2024.

**Q: What is the expected growth for Hospitals and Clinics by 2035?**
A: The Hospitals and Clinics segment is expected to grow from $3.75 Million in 2024 to $4.5 Million by 2035.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/south-america-non-alcoholic-steatohepatitis-biomarkers-market-49718*